Treat to Target (T2T) in Gout Trial
The T2T trial is a randomised controlled trial (RCT) designed to test the clinical and cost-effectiveness of using a goal-directed allopurinol-based-treat to target approach in people with recurrent gout flares.
The T2T trial is working with clinical research networks and GP practices in the UK in the regions of East Midlands, North Thames, Thames Valley and South Midlands, West Midlands, Wessex and Yorkshire and Humber.
The website will be used as a communication hub for sites and trained staff.
| Study Title | What is the clinical effectiveness of using a goal-directed allopurinol-based treat to target protocol in people with recurrent gout flares? |
| Short Title | T2T |
| Chief Investigator | 
Professor A Abhishek |
| Sponsor | University of Nottingham |
| IRAS Number | 263669 |
| REC Number | 19/NW/0310 |
| ISRCTN | 12059648 |
| CPMS | 42053 |
| Funder | NIHR Health Technology Assessment (HTA) |
| Grant Number |
17/82/02 |
| Trial management |
Keele Clinical Trials Unit, Tel: +44 (0)1782 732950, E-mail: ctu.t2tgout@keele.ac.uk |
Privacy Policy
Keele University is the joint data controller with the University of Nottingham for the T2T study data, and hence require that Keele University and University of Nottingham privacy notices are made available to individual requests for information about how we process any personal information about an individual.
Funding Notice
This study is funded by the National Institute for Health Research (NIHR) [Health Technology Assessment (HTA) programme (17/82/02)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Contact Us
Telephone: +44 (0)1782 732950
Email: ctu.t2tgout@keele.ac.uk